Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

atorvastatin

Known as: (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid 
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… Expand
National Institutes of Health

Related topics

Related topics

36 relations
Amlodipine / atorvastatinAmlodipine 5 MG / atorvastatin 80 MG Oral Tablet [Caduet]Atorvastatin SodiumAtorvastatin calcium
Expand

Broader (2)

Anticholesteremic AgentsPyrroles

Narrower (6)

CI 981CaduetLipitorLiptruzet
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Background and Purpose— The purpose of these guidelines is to provide an up-to-date comprehensive set of recommendations for… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2006
Highly Cited
2006
High-dose atorvastatin after stroke or transient ischemic attack.
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2005
Highly Cited
2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Background Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit… Expand
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
background Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
BACKGROUND Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2005
Highly Cited
2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2005
Highly Cited
2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
BACKGROUND Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit… Expand
  • figure 1
  • table 1
  • table 1
  • figure 2
  • figure 3
Highly Cited
2004
Highly Cited
2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
BACKGROUND Type 2 diabetes is associated with a substantially increased risk of cardiovascular disease, but the role of lipid… Expand
  • figure 1
  • table 2
  • figure 2
  • table 3
  • figure 3
Highly Cited
2003
Highly Cited
2003
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE